SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-08-28
Accession Number: 0001213900-24-073419
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390024073419/ea020832406ex1-1_synergy.htm

Chunk 0 of 15
Word Count: 1479
Character Count: 9642

Document Content:

Exhibit 1.1

SYNERGY
CHC CORP.

UNDERWRITING
AGREEMENT

Shares of Common Stock

Roth
Capital Partners, LLC

the Representative of the

Several
Underwriters Named on Schedule I hereto

Roth Capital Partners, LLC888 San Clemente Drive, Suite 400

Newport
Beach, CA 92660

Ladies
and Gentlemen:

Synergy
CHC Corp., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein,
to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”),
for whom Roth Capital Partners, LLC is acting as the representative (the “Representative”), an aggregate of [●]
authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.00001 per share (the “Common
Stock”), of the Company and also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4
hereof, up to an additional [●] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option
Shares are hereinafter collectively referred to as the “Shares”. The Shares, the Underwriter Warrants (as defined
below) and the Underwriter Warrant Shares (as defined below) are collectively referred to as the “Securities.”

The
Company and the several Underwriters hereby confirm their agreement as follows:

1. Registration
Statement and Prospectus.

The
Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration statement
covering the Securities on Form S-1 (File No. 333-280556) under the Securities Act of 1933, as amended (the “Securities Act”),
and the rules and regulations (the “Rules and Regulations”) of the Commission thereunder, and such amendments to such
registration statement (including post effective amendments) as may have been required to the date of this Agreement. Such registration
statement, as amended (including any post effective amendments), has been declared effective by the Commission. Such registration statement,
including amendments thereto (including post effective amendments thereto) at the time of effectiveness thereof (the “Effective
Time”), the exhibits and any schedules thereto at the Effective Time or thereafter during the period of effectiveness and the
documents and information otherwise deemed to be a part thereof or included therein by the Securities Act or otherwise pursuant to the
Rules and Regulations at the Effective Time or thereafter during the period of effectiveness, is herein called the “Registration
Statement.” If the Company has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities
Act (the “Rule 462 Registration Statement”), then any reference herein to the term Registration Statement shall include
such Rule 462 Registration Statement. Any preliminary prospectus included in the Registration Statement or filed with the Commission
pursuant to Rule 424(a) under the Securities Act is hereinafter called a “Preliminary Prospectus.” The Preliminary
Prospectus relating to the Securities that was included in the Registration Statement immediately prior to the pricing of the offering
contemplated hereby is hereinafter called the “Pricing Prospectus.”

The
Company is filing with the Commission pursuant to Rule 424 under the Securities Act a final prospectus covering the Securities, which
includes the information permitted to be omitted therefrom at the Effective Time by Rule 430A under the Securities Act. Such final prospectus,
as so filed, is hereinafter called the “Final Prospectus.” The Final Prospectus, the Pricing Prospectus and any preliminary
prospectus in the form in which they were included in the Registration Statement or filed with the Commission pursuant to Rule 424 under
the Securities Act is hereinafter called a “Prospectus.”

The
Commission has not notified the Company of any objection to the use of form of Registration Statement or any post-effective amendment
thereto.

2. Representations
and Warranties of the Company Regarding the Offering.

(a) The
Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof, and as of the Closing Date (as
defined in Section 4(d) below) and as of each Option Closing Date (as defined in Section 4(b) below), as follows:

Material Misstatements or Omissions. At each time of effectiveness, at the date hereof, at the Closing Date, and at each Option Closing
Date, if any, the Registration Statement and any post-effective amendment thereto complied or will comply in all material respects with
the requirements of the Securities Act and the Rules and Regulations and did not, does not, and will not, as the case may be, contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The Time of Sale Disclosure Package (as defined in Section 2(a)(iv)(A)(1) below) as of [●] (Eastern time)
(the “Applicable Time”) on the date hereof, and at the Closing Date and on each Option Closing Date, if any, and the
Final Prospectus, as amended or supplemented, as of its date, at the time of filing pursuant to Rule 424(b) under the Securities Act,
and at the Closing Date and at each Option Closing Date, if any, and any individual Written Testing-the-Waters Communication, when considered
together with the Time of Sale Disclosure Package, did not, does not and will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences shall
not apply to statements in or omissions from the Registration Statement, the Time of Sale Disclosure Package or any Prospectus in reliance
upon, and in conformity with, written information furnished to the Company by any Underwriter specifically for use in the preparation
thereof, which written information is described in Section 7(f). The Registration Statement contains all exhibits and schedules required
to be filed by the Securities Act or the Rules and Regulations. No order preventing or suspending the effectiveness or use of the Registration
Statement or any Prospectus is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge
of the Company, are contemplated or threatened by the Commission.

(ii) Marketing
Materials. The Company has not distributed any prospectus or other offering material in connection with the offering and sale of
the Shares other than the Time of Sale Disclosure Package and the roadshow or investor presentations delivered to and approved by the
Representative for use in connection with the marketing of the offering of the Securities (the “Marketing Materials”).

(iii) Testing-the-Waters
Communications. The Company (i) has not alone engaged in any Testing-the-Waters Communication and (ii) has not authorized
anyone other than the Representative to engage in Testing-the-Waters Communications. The Company has not distributed any Testing-the-Waters
Communication that is a written communication within the meaning of Rule 405 under the Securities Act
(“Written Testing-the-Waters Communications”), other than those previously provided to the Representative and
listed on Schedule IV hereto. “Testing-the-Waters Communication” means
any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.
Each Written Testing-the-Waters Communications, did not, as of the Applicable Time, and
at all times through the completion of the public offer and sale of Shares will not, include
any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the
Time of Sale Disclosure Package and the Final Prospectus.

(iv) Accurate
Disclosure. (A) The Company has provided a copy to the Underwriters of each Issuer Free Writing Prospectus (as defined below) used
in the sale of Shares.  The Company has filed all Issuer Free Writing Prospectuses required to be so filed with the Commission,
and no order preventing or suspending the effectiveness or use of any Issuer Free Writing Prospectus is in effect and no proceedings
for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission.
When taken together with the rest of the Time of Sale Disclosure Package or the Final Prospectus,  no Issuer Free Writing Prospectus,
as of its issue date and at all subsequent times though the completion of the public offer and sale of Shares, has, does or will include
(1) any untrue statement of a material fact or omission to state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, or (2) information that conflicted, conflicts
or will conflict with the information contained in the Registration Statement or the Final Prospectus. The representations and warranties
set forth in the immediately preceding sentence shall not apply to statements in or omissions from the Time of Sale Disclosure Package,
the Final Prospectus or any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to
the Company by any Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f). As
used in this paragraph and elsewhere in this Agreement: